Cardiff Oncology to Present at the Jefferies Healthcare Conference
Cardiff Oncology to Present at the Jefferies Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024.
2024年5月29日聖地亞哥（美通社）——Cardiff Oncology卡迪夫生物技術公司（Nasdaq: CRDF）是一家臨床階段的生物技術公司，利用PLK1抑制劑開發一系列癌症新療法，今天宣佈公司管理層將參與Jefferies Healthcare Conference上的公司演示和1x1投資者會議，該會議將於2024年6月5-6日在紐約萬豪酒店舉行。
Details of the presentations can be found below.
演示的詳細信息如下。
Presenters: Mark Erlander, CEO
Date: June 5, 2024
Time: 8:30 – 8:55 AM ET in Track 8
主講人：Mark Erlander，首席執行官
日期：2024年6月5日
時間：美國東部時間8:30 - 8:55 AM，位於第八軌道。
Interested parties can register for and access the live webcasts for these conferences by visiting the "Events" section of the Cardiff Oncology website. The webcast replays will be available after the conclusion of the respective presentations.
有興趣的團體可以訪問Cardiff Oncology網站的“Events”欄目註冊並訪問這些會議的現場網絡廣播。在各自的演示結束後，網絡廣播重播將可用。
About Cardiff Oncology, Inc.
關於Cardiff Oncology, Inc.卡迪夫生物技術公司
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit
Cardiff Oncology是一家臨床階段的生物技術公司，利用PLK1抑制劑這一經過驗證的腫瘤藥物靶點，開發一系列癌症新療法。該公司的主要資產是onvansertib，這是一種PLK1抑制劑，正在臨床試驗中與標準治療（SoC）療法聯合使用，針對RAS突變轉移性結直腸癌（mCRC）等適應症，以及在轉移性胰腺導管腺癌（mPDAC）、小細胞肺癌（SCLC）和三陰性乳腺癌（TNBC）的調查者發起的試驗中使用。這些計劃和公司的更廣泛的發展策略旨在針對腫瘤易感性，以克服治療抵抗和與SoC單獨相比提供優越的臨床利益。有關更多信息，請訪問：
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Cardiff Oncology聯繫方式：
James Levine
致富金融
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
投資者聯繫人：
Kiki Patel，藥劑博士
吉爾馬汀集團
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Grace Spencer
Taft Communications
609-583-1151
grace@taftcommunications.com
媒體聯繫人：
格雷絲·斯賓塞
Taft Communications
609-583-1151
grace@taftcommunications.com
譯文內容由第三人軟體翻譯。